Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.

Adult Antiviral Agents / pharmacology Arthritis, Rheumatoid / drug therapy Autoimmune Diseases / drug therapy Cohort Studies Drug Therapy, Combination / methods Female Hepatitis C / complications Hepatitis C, Chronic / complications Humans Incidence Interferon-alpha / pharmacology Lupus Erythematosus, Systemic / drug therapy Male Middle Aged Polyethylene Glycols / pharmacology Proportional Hazards Models Ribavirin / pharmacology Sustained Virologic Response Taiwan / epidemiology Viral Load / drug effects

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 03 2020
Historique:
received: 12 11 2019
accepted: 05 03 2020
entrez: 28 3 2020
pubmed: 28 3 2020
medline: 5 1 2021
Statut: epublish

Résumé

In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m

Identifiants

DOI: 10.1038/s41598-020-61991-3 PMID: 32214132 PMC: PMC7096452
pubmed: 32214132
doi: 10.1038/s41598-020-61991-3
pii: 10.1038/s41598-020-61991-3
pmc: PMC7096452
doi:

Substances chimiques

Antiviral Agents 0
Interferon-alpha 0
Polyethylene Glycols 3WJQ0SDW1A
Ribavirin 49717AWG6K

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5372

Références

El-Serag, H. B., Hampel, H., Yeh, C. & Rabeneck, L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36, 1439–1445, https://doi.org/10.1053/jhep.2002.37191 (2002).
doi: 10.1053/jhep.2002.37191 pubmed: 12447870
Cacoub, P. et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42, 2204–2212, https://doi.org/10.1002/1529-0131(199910)42:10##2204::AID-ANR24$$3.0.CO;2-D (1999).
doi: 10.1002/1529-0131(199910)42:10##2204::AID-ANR24$$3.0.CO;2-D pubmed: 10524695
Jacobson, I. M., Cacoub, P., Dal Maso, L., Harrison, S. A. & Younossi, Z. M. Manifestations of chronic hepatitis C virus infection beyond the liver. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 8, 1017–1029, https://doi.org/10.1016/j.cgh.2010.08.026 (2010).
doi: 10.1016/j.cgh.2010.08.026
Hsu, Y. C. et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64, 495–503, https://doi.org/10.1136/gutjnl-2014-308163 (2015).
doi: 10.1136/gutjnl-2014-308163 pubmed: 25398770
Panel, A.-I. H. G. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 67, 1477–1492, https://doi.org/10.1093/cid/ciy585 (2018).
doi: 10.1093/cid/ciy585
European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L. EASL Recommendations on Treatment of Hepatitis C 2018. Journal of hepatology 69, 461–511, https://doi.org/10.1016/j.jhep.2018.03.026 (2018).
Buskila, D. Hepatitis C-associated arthritis. Curr Opin Rheumatol 12, 295–299, https://doi.org/10.1097/00002281-200007000-00011 (2000).
doi: 10.1097/00002281-200007000-00011 pubmed: 10910182
Palazzi, C., Olivieri, I., Cacciatore, P., Pennese, E. & D’Amico, E. Management of hepatitis C virus-related arthritis. Expert Opin Pharmacother 6, 27–34, https://doi.org/10.1517/14656566.6.1.27 (2005).
doi: 10.1517/14656566.6.1.27 pubmed: 15709880
Lormeau, C., Falgarone, G., Roulot, D. & Boissier, M. C. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 73, 633–638, https://doi.org/10.1016/j.jbspin.2006.05.005 (2006).
doi: 10.1016/j.jbspin.2006.05.005 pubmed: 17056293
Dore, M. P., Fattovich, G., Sepulveda, A. R. & Realdi, G. Cryoglobulinemia related to hepatitis C virus infection. Dig. Dis. Sci. 52, 897–907, https://doi.org/10.1007/s10620-006-9510-9 (2007).
doi: 10.1007/s10620-006-9510-9 pubmed: 17380399
Ramos-Casals, M. et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis and rheumatism 43, 2801–2806, https://doi.org/10.1002/1529-0131(200012)43:12##2801::AID-ANR21$$3.0.CO;2-V (2000).
doi: 10.1002/1529-0131(200012)43:12##2801::AID-ANR21$$3.0.CO;2-V pubmed: 11145039
Ahmed, M. M. et al. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. The American journal of the medical sciences 331, 252–256, https://doi.org/10.1097/00000441-200605000-00003 (2006).
doi: 10.1097/00000441-200605000-00003 pubmed: 16702794
Manns, M. P. & Rambusch, E. G. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J. Hepatol. 31(Suppl 1), 39–42, https://doi.org/10.1016/s0168-8278(99)80372-9 (1999).
doi: 10.1016/s0168-8278(99)80372-9 pubmed: 10622558
Machida, K. et al. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 80, 866–874, https://doi.org/10.1128/JVI.80.2.866-874.2006 (2006).
doi: 10.1128/JVI.80.2.866-874.2006 pubmed: 16378988 pmcid: 1346849
Peveling-Oberhag, J., Arcaini, L., Hansmann, M. L. & Zeuzem, S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. Journal of hepatology 59, 169–177, https://doi.org/10.1016/j.jhep.2013.03.018 (2013).
doi: 10.1016/j.jhep.2013.03.018 pubmed: 23542089
Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938–941, https://doi.org/10.1126/science.282.5390.938 (1998).
doi: 10.1126/science.282.5390.938 pubmed: 9794763
Dammacco, F. et al. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Seminars in liver disease 20, 143–157, https://doi.org/10.1055/s-2000-9613 (2000).
doi: 10.1055/s-2000-9613 pubmed: 10946420
See, L. C., Kuo, C. F., Chou, I. J., Chiou, M. J. & Yu, K. H. Sex- and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study. Semin Arthritis Rheum 43, 381–386, https://doi.org/10.1016/j.semarthrit.2013.06.001 (2013).
doi: 10.1016/j.semarthrit.2013.06.001 pubmed: 23916348
Escalante, A., Haas, R. W. & del Rincon, I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165, 1624–1629, https://doi.org/10.1001/archinte.165.14.1624 (2005).
doi: 10.1001/archinte.165.14.1624 pubmed: 16043681
Li, H. M. et al. Plasma/Serum Leptin Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis. Arch. Med. Res. 46, 551–556, https://doi.org/10.1016/j.arcmed.2015.09.005 (2015).
doi: 10.1016/j.arcmed.2015.09.005 pubmed: 26452329
Landau, D. A. et al. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. The Journal of rheumatology 37, 615–621, https://doi.org/10.3899/jrheum.090790 (2010).
doi: 10.3899/jrheum.090790 pubmed: 20110523
Younossi, Z., Park, H., Henry, L., Adeyemi, A. & Stepanova, M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 150, 1599–1608, https://doi.org/10.1053/j.gastro.2016.02.039 (2016).
doi: 10.1053/j.gastro.2016.02.039 pubmed: 26924097
Ramos-Casals, M. et al. Sjogren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore) 84, 81–89, https://doi.org/10.1097/01.md.0000157397.30055.c9 (2005).
doi: 10.1097/01.md.0000157397.30055.c9
Cacoub, P. et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 79, 47–56, https://doi.org/10.1097/00005792-200001000-00005 (2000).
doi: 10.1097/00005792-200001000-00005
Scheuer, P. J. Classification of chronic viral hepatitis: a need for reassessment. Journal of hepatology 13, 372–374, https://doi.org/10.1016/0168-8278(91)90084-o (1991).
doi: 10.1016/0168-8278(91)90084-o pubmed: 1808228
Castera, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343–350, https://doi.org/10.1053/j.gastro.2004.11.018 (2005).
doi: 10.1053/j.gastro.2004.11.018 pubmed: 15685546
Lin, Y. H. et al. The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. The Kaohsiung journal of medical sciences 32, 362–366, https://doi.org/10.1016/j.kjms.2016.05.008 (2016).
doi: 10.1016/j.kjms.2016.05.008 pubmed: 27450025
Gray, R. J. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. The Annals of Statistics 16, 1141–1154, https://doi.org/10.1214/aos/1176350951 (1988).
doi: 10.1214/aos/1176350951
Fine, J. P. & Gray, R. J. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J. Am. Stat. Assoc. 94, 496–509, https://doi.org/10.2307/2670170 (1999).
doi: 10.2307/2670170

Auteurs

Wei-Fan Hsu (WF)

Center for Digestive Disease, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan.
ORCID: 0000-0002-0738-417X

Chi-Yi Chen (CY)

Department of Internal Medicine, Chiayi Christian Hospital, Chiayi, Taiwan.

Kuo-Chih Tseng (KC)

Department of Gastroenterology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.

Hsueh-Chou Lai (HC)

Center for Digestive Disease, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
School of Chinese Medicine, China Medical University, Taichung, Taiwan.

Hsing-Tao Kuo (HT)

Division of Hepato-gastroenterology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.

Chao-Hung Hung (CH)

Division of Hepatogastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.

Shui-Yi Tung (SY)

Division of Hepatogastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.

Jing-Houng Wang (JH)

Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Jyh-Jou Chen (JJ)

Division of Gastroenterology and Hepatology, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.

Pei-Lun Lee (PL)

Division of Gastroenterology and Hepatology, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.

Rong-Nan Chien (RN)

Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Chun-Yen Lin (CY)

Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
ORCID: 0000-0003-3007-3190

Chi-Chieh Yang (CC)

Division of Gastroenterology, Department of Internal Medicine, Show-Chwan Memorial Hospital, Changhua, Taiwan.

Gin-Ho Lo (GH)

Division of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

Chi-Ming Tai (CM)

Division of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

Chih-Wen Lin (CW)

Division of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

Jia-Horng Kao (JH)

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Division of Gastroenterology and Hepatology, the National Taiwan University Hospital, Taipei, Taiwan.
ORCID: 0000-0002-2442-7952

Chun-Jen Liu (CJ)

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Division of Gastroenterology and Hepatology, the National Taiwan University Hospital, Taipei, Taiwan.
ORCID: 0000-0001-8082-7144

Chen-Hua Liu (CH)

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Division of Gastroenterology and Hepatology, the National Taiwan University Hospital, Taipei, Taiwan.
ORCID: 0000-0003-3622-9707

Sheng-Lei Yan (SL)

Division of Gastroenterology, Department of Internal Medicine, Chang Bing Show-Chwan Memorial Hospital, Changhua, Taiwan.

Ming-Jong Bair (MJ)

Division of Gastroenterology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung, Taiwan.

Wei-Wen Su (WW)

Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.

Cheng-Hsin Chu (CH)

Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.

Chih-Jen Chen (CJ)

Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.

Ching-Chu Lo (CC)

Department of Internal Medicine, St. Martin De Porres Hospital - Daya, Chiayi, Taiwan.

Pin-Nan Cheng (PN)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital; College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID: 0000-0001-9331-9018

Yen-Cheng Chiu (YC)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital; College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Chia-Chi Wang (CC)

Division of Gastroenterology, Department of Internal Medicine, Taipei Tzuchi Hospital, New Taipei City, Taiwan.

Jin-Shiung Cheng (JS)

Division of Gastroenterology and Hepatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.

Wei-Lun Tsai (WL)

Division of Gastroenterology and Hepatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.

Han-Chieh Lin (HC)

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Yi-Hsiang Huang (YH)

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
ORCID: 0000-0001-5241-5425

Pei-Chien Tsai (PC)

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
School of Medicine and Hepatitis Research Center, College of Medicine, and Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

Jee-Fu Huang (JF)

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
School of Medicine and Hepatitis Research Center, College of Medicine, and Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

Chia-Yen Dai (CY)

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
School of Medicine and Hepatitis Research Center, College of Medicine, and Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

Wan-Long Chuang (WL)

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
School of Medicine and Hepatitis Research Center, College of Medicine, and Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

Ming-Lung Yu (ML)

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. fish6069@gmail.com.
School of Medicine and Hepatitis Research Center, College of Medicine, and Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan. fish6069@gmail.com.
ORCID: 0000-0001-8145-1900

Cheng-Yuan Peng (CY)

Center for Digestive Disease, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. cypeng@mail.cmuh.org.tw.
School of Medicine, China Medical University, Taichung, Taiwan. cypeng@mail.cmuh.org.tw.
ORCID: 0000-0001-9030-6086

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sustained virological response to hepatitis C...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Sustained virological response to hepatitis C...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Polyarthrite rhumatoïde › Sustained virological response to hepatitis C...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Sustained virological response to hepatitis C...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Sustained virological response to hepatitis C...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Sustained virological response to hepatitis C...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Hépatite › Hépatites virales humaines › Hépatite C › Sustained virological response to hepatitis C...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Hépatite chronique › Hépatite C chronique › Sustained virological response to hepatitis C...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Sustained virological response to hepatitis C...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Sustained virological response to hepatitis C...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Interféron alpha › Sustained virological response to hepatitis C...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › Sustained virological response to hepatitis C...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Sustained virological response to hepatitis C...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › Sustained virological response to hepatitis C...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Modèles des risques proportionnels › Sustained virological response to hepatitis C...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Ribavirine › Sustained virological response to hepatitis C...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Réponse virologique soutenue › Sustained virological response to hepatitis C...
questionsmedicales.fr › Régions géographiques › Iles › Taïwan › Sustained virological response to hepatitis C...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Charge virale › Sustained virological response to hepatitis C...